Karyopharm Therapeutics Inc (NASDAQ:KPTI) insider Sharon Shacham sold 10,000 shares of the stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $10.08, for a total transaction of $100,800.00. Following the transaction, the insider now directly owns 723,510 shares in the company, valued at approximately $7,292,980.80. The transaction was disclosed in a filing with the SEC, which is available through this link.

Sharon Shacham also recently made the following trade(s):

  • On Thursday, December 7th, Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.39, for a total transaction of $103,900.00.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) traded up $0.02 on Tuesday, hitting $10.08. 112,249 shares of the company were exchanged, compared to its average volume of 184,133. Karyopharm Therapeutics Inc has a 12 month low of $7.48 and a 12 month high of $14.63. The firm has a market cap of $475.58, a price-to-earnings ratio of -3.79 and a beta of 4.08.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. equities research analysts expect that Karyopharm Therapeutics Inc will post -2.58 EPS for the current year.

A number of research firms have recently issued reports on KPTI. Jefferies Group reissued a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, October 13th. Cantor Fitzgerald reissued a “buy” rating and set a $18.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, September 20th. Zacks Investment Research cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. HC Wainwright reissued a “buy” rating and set a $23.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, December 12th. Finally, BidaskClub raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $17.33.

Several institutional investors and hedge funds have recently bought and sold shares of KPTI. Schwab Charles Investment Management Inc. raised its holdings in shares of Karyopharm Therapeutics by 34.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 116,036 shares of the company’s stock worth $1,051,000 after acquiring an additional 29,522 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Karyopharm Therapeutics by 8.8% in the 2nd quarter. Rhumbline Advisers now owns 74,812 shares of the company’s stock worth $677,000 after acquiring an additional 6,025 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth about $235,000. Swiss National Bank raised its holdings in shares of Karyopharm Therapeutics by 39.2% in the 2nd quarter. Swiss National Bank now owns 56,850 shares of the company’s stock worth $514,000 after acquiring an additional 16,000 shares during the last quarter. Finally, Alliancebernstein L.P. raised its holdings in shares of Karyopharm Therapeutics by 31.9% in the 2nd quarter. Alliancebernstein L.P. now owns 43,430 shares of the company’s stock worth $393,000 after acquiring an additional 10,500 shares during the last quarter. Institutional investors own 60.92% of the company’s stock.

WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/09/karyopharm-therapeutics-inc-kpti-insider-sells-100800-00-in-stock.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.